DRUG logo

DRUG
Bright Minds Biosciences Inc

7,611
Mkt Cap
$699.39M
Volume
188,468.00
52W High
$123.75
52W Low
$23.18
PE Ratio
-36.84
DRUG Fundamentals
Price
$71.46
Prev Close
$71.72
Open
$70.06
50D MA
$78.17
Beta
0.99
Avg. Volume
146,482.92
EPS (Annual)
-$1.27
P/B
8.54
$357.67
Loading...
Loading...
News
all
press releases
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG Research
BTIG Research reissued a "buy" rating and issued a $147.00 target price on shares of Bright Minds Biosciences in a research note on Monday...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Moderate Buy" from Brokerages
Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the firm, MarketBeat.com reports. One...
MarketBeat·8d ago
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Raised to "Hold" at Wall Street Zen
Wall Street Zen upgraded Bright Minds Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·15d ago
News Placeholder
303,685 Shares in Bright Minds Biosciences Inc. $DRUG Acquired by Braidwell LP
Braidwell LP acquired a new stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional...
MarketBeat·21d ago
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Expected to Rise, HC Wainwright Analyst Says
HC Wainwright boosted their price objective on Bright Minds Biosciences from $115.00 to $145.00 and gave the stock a "buy" rating in a report on Wednesday...
MarketBeat·1mo ago
News Placeholder
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Average Recommendation of "Moderate Buy" by Brokerages
Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat...
MarketBeat·1mo ago
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen cut shares of Bright Minds Biosciences from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·1mo ago
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap Up - What's Next?
Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap Up - What's Next...
MarketBeat·1mo ago
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Up 7.9% - Here's What Happened
Bright Minds Biosciences (NASDAQ:DRUG) Trading 7.9% Higher - Still a Buy...
MarketBeat·2mo ago
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG Research
BTIG Research reissued a "buy" rating and issued a $147.00 price objective on shares of Bright Minds Biosciences in a research report on Tuesday...
MarketBeat·2mo ago
<
1
2
...
>

Latest DRUG News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.